End-of-day quote
Korea S.E.
23:00:00 13/06/2024 BST
|
5-day change
|
1st Jan Change
|
3,145
KRW
|
+0.96%
|
|
+8.82%
|
-3.97%
|
04-26 |
ADBiotech Co., Ltd. announced that it has received KRW 4.5 billion in funding from Kiwoom Securities Co., Ltd., NH Investment & Securities Co., Ltd., Samsung Securities Co.,Ltd., Mirae Asset Securities Co., Ltd., KB Securities Co.,Ltd
|
CI
| 04-25 |
ADBiotech Co., Ltd. announced that it expects to receive KRW 4.5 billion in funding from Kiwoom Securities Co., Ltd., NH Investment & Securities Co., Ltd., Samsung Securities Co.,Ltd., Mirae Asset Securities Co., Ltd., KB Securities Co.,Ltd
|
CI
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
37,494
|
45,092
|
30,712
|
29,935
|
Enterprise Value (EV)
1 |
41,890
|
55,480
|
34,855
|
34,131
|
P/E ratio
|
-5.15
x
|
-26.2
x
|
28.3
x
|
-10.5
x
|
Yield
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
3.82
x
|
3.81
x
|
2.89
x
|
2.86
x
|
EV / Revenue
|
4.27
x
|
4.69
x
|
3.28
x
|
3.26
x
|
EV / EBITDA
|
-51.4
x
|
-61.4
x
|
-8.19
x
|
-9.38
x
|
EV / FCF
|
-
|
-11,182,540
x
|
-10,732,842
x
|
-27,117,975
x
|
FCF Yield
|
-
|
-0%
|
-0%
|
-0%
|
Price to Book
|
4.05
x
|
13.7
x
|
1.9
x
|
2.24
x
|
Nbr of stocks (in thousands)
|
4,955
|
4,955
|
9,140
|
9,140
|
Reference price
2 |
7,567
|
9,100
|
3,360
|
3,275
|
Announcement Date
|
16/03/22
|
16/03/22
|
22/03/23
|
20/03/24
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
9,815
|
11,840
|
10,632
|
10,472
|
EBITDA
1 |
-815.1
|
-903
|
-4,258
|
-3,639
|
EBIT
1 |
-996.2
|
-1,555
|
-4,984
|
-4,772
|
Operating Margin
|
-10.15%
|
-13.13%
|
-46.88%
|
-45.57%
|
Earnings before Tax (EBT)
1 |
-7,476
|
-2,415
|
2,696
|
-5,457
|
Net income
1 |
-7,345
|
-2,664
|
2,696
|
-2,863
|
Net margin
|
-74.83%
|
-22.5%
|
25.36%
|
-27.34%
|
EPS
2 |
-1,470
|
-347.0
|
118.5
|
-313.3
|
Free Cash Flow
|
-
|
-4,961
|
-3,247
|
-1,259
|
FCF margin
|
-
|
-41.9%
|
-30.55%
|
-12.02%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
Announcement Date
|
16/03/22
|
16/03/22
|
22/03/23
|
20/03/24
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
4,396
|
10,388
|
4,143
|
4,196
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-5.393
x
|
-11.5
x
|
-0.973
x
|
-1.153
x
|
Free Cash Flow
|
-
|
-4,961
|
-3,247
|
-1,259
|
ROE (net income / shareholders' equity)
|
-
|
-36.9%
|
25.3%
|
-37.8%
|
ROA (Net income/ Total Assets)
|
-
|
-4.88%
|
-12%
|
-10.1%
|
Assets
1 |
-
|
54,571
|
-22,497
|
28,374
|
Book Value Per Share
2 |
1,866
|
664.0
|
1,771
|
1,465
|
Cash Flow per Share
2 |
488.0
|
155.0
|
129.0
|
330.0
|
Capex
1 |
5,289
|
3,561
|
727
|
240
|
Capex / Sales
|
53.89%
|
30.08%
|
6.84%
|
2.29%
|
Announcement Date
|
16/03/22
|
16/03/22
|
22/03/23
|
20/03/24
|
|
1st Jan change
|
Capi.
|
---|
| -3.97% | 20.77M | | +21.01% | 8.91B | | +21.62% | 3.6B | | -5.56% | 3.04B | | +13.68% | 1.67B | | -5.27% | 1.23B | | -29.81% | 1.16B | | -31.11% | 1.15B | | -22.47% | 1.01B | | -12.32% | 916M |
Veterinary Drugs
|